Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension

Journal of Hypertension

Volumn 16, Issue 5, 1998, Pages 689-696

  Gerritsen, Tanneke A ^a   Bak, Annette A A ^a   Stolk, Ronald P ^a   Jonker, Jan J C ^b   Grobbee, Diederick E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Andro Medical Research   (Netherlands)

Author keywords

Angiotensin converting enzyme inhibitor; Calcium antagonist; Hypertension; Left ventricular mass; Non insulin dependent diabetes mellitus

Indexed keywords

CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NITRENDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

EID: 0031971980     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816050-00017     Document Type: Article

References (39)

1. Devereux RB, Roman MJ. Hypertensive cardiac hypertrophy: pathophysiologic and clinical characteristics. In: Laragh JH, Brenner BM (editors): Hypertension: pathophysiology, diagnosis, management. New York: Raven Press, Ltd; 1995. pp. 409-433.
2. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, et al. The heart in hypertension. N Engl J Med 1992; 327:998-1008.
3. Casale PN, Devereux RB, Milner M, Zullo G, Harsfield GA, Pickering TG, et al. Value of echocardiographic measurements of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105:173-178.
4. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort: the Framingham Heart Study. Ann Intern Med 1989; 110:101-107.
6. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
7. Chambers J. Left ventricular hypertrophy [editorial]. BMJ 1995; 311:273-274.
8. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275:1507-1513.
9. Liebson PR, Grandits GA, Dianzumba S, Prineas PJ, Grimm RHJ, Neaton JD, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91:698-706.
10. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ, for the VA Cooperative Study Group on Antihypertensive Agents. Effects of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation 1997; 95:2007-2014.
11. Kelleher C, Kingston SM, Barry DG, Cole MM, Ferris JB, Grealy G, et al. Hypertension in diabetic clinic patients and their siblings. Diabetologia 1988; 31:76-81.
12. Teuscher A, Egger M, Herman JB. Diabetes and hypertension. Blood pressure in clinical diabetic patients and a control population. Arch Intern Med 1989; 149:1942-1945.
13. Reaven PD, Barrett-Connor EL, Browner DK. Abnormal glucose tolerance and hypertension. Diabetes Care 1990; 13:119-125.
14. Fuller JH. Hypertension and diabetes: epidemiologic aspects as a guide to management. J Cardiovasc Pharmacol 1993; 21 (suppl 2):S63-S66.
15. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994; 17:1247-1251.
16. Ferrari P, Weidman P. Insulin, insulin sensitivity and hypertension. J Hypertens 1990; 8:491-500.
17. Reaven GM. Relationship between insulin resistance and hypertension. Diabetes Care 1991; 14 (suppl 4):33-38.
18. Galderisi M, Anderson KM, Wilson PWF, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy. (The Framingham Heart Study). Am J Cardiol 1991; 68:85-89.
19. Vanninen E, Mustonen J, Vainio P, Länsimies E, Uusitupa M. Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus. Am J Cardiol 1992; 70:371-378.
20. Lind L, Andersson PE, Andren B, Hänni A, Lithell HO. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens 1995; 13:433-438.
21. Lonn EM, Gerstein HC, Shaikholeslami R, Pogue J, Yusuf S. Diabetes is an independent risk factor for increased left ventricular mass [abstract]. Circulation 1996; 94 (suppl 8):1501.
22. Stein PP, Black HR. Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care 1991; 14:425-448.
23. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991; 14:203-209.
24. Weidmann P, Boehlen LM, de Courten M, Ferrari P. Antihypertensive therapy in diabetic patients. J Hum Hypertens 1992; 6 (suppl 2): S23-S36.
25. 2+ channel antagonists, and α-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 1995; 44:665-671.
26. Devereux RB, Alono DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
27. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55:613-618.
28. Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17:863.
29. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eissenberg RR, Hammond IW, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4:1222-1230.
30. Fagerberg B, Wikstrand J, Berglund G, Hartford M, Ljungman S, Wendelhag I. Withdrawal of antihypertensive drug treatment: time-course for redevelopment of hypertension and effects upon left ventricular mass. J Hypertens 1992; 10:587-593.
31. Guigliano D, De Rosa N, Marfella R, Di Maro G, Cacciapuoti F, Quatraro A. et al. Comparison of nitrendipine and cilazapril in patients with hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens 1993; 6:927-932.
32. Holdaway IM, Gamble GD, Sanders GA, Greaves SC, Ellis-Pegler EM, Sharpe N. Effect of fosinopril on cardiac and metabolic parameters in patients with NIDDM. Diabetes Care 1994; 17:1476-1479.
33. Scognamiglio R, Nosadini R, Marin M, Nisti S, Fasoli G, Palisi M, et al. Evaluation of the efficacy and tolerability of nitrendipine in reducing both pressure and left ventricular mass in hypertensive type 2 diabetic patients. Diabetes Care 1997; 20:1290-1292.
34. Resnick LM. Cellular calcium and magnesium metabolism? The pathophysiology and treatment of hypertension and related metabolic disorders. Am J Med 1992; 93 (suppl 2A):11S-20S.
35. Barbagallo M, Gupta RK, Resnick LM. Cellular ions in NIDDM: relation of calcium to hyperglycemia and cardiac mass. Diabetes Care 1996; 19:1393-1398.
36. Barbagallo M, Novo S, Licata G, Resnick LM. Diabetes, hypertension and atherosclerosis: pathophysiological role of intracellular ions. Int Angiol 1993; 12:365-370.
37. Hsueh WA, Anderson PW. Systemic hypertension and the renin-angiotensin system in diabetic vascular complications. Am J Cardiol 1993; 72:14H-21H.
38. Savage PJ. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann Intern Med 1996; 124:123-126.
39. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.